A Phase 2 interventional study of SYH2066 and Placebo in Respiratory Syncytial Virus Infections, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 11 of the 12 other live ones, and was the 30th registered.
306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.
Browse Respiratory Syncytial Virus Infections studies →8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:
Ab&B Bio-tech Co., Ltd.JS · Sites in China
Ages 18+ · Healthy volunteers
Simcere Pharmaceutical Co., Ltd · Sites in China
Ages 1 mo–36 mo
Shanghai Ark Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–85
Kexing Biopharm Co., Ltd. · Sites in China
Ages 2 mo–2 yrs
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–45 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 13 · Phase 3 10
First in 2019; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 80 is below the median of 89 across 223 interventional studies indexed under Respiratory Syncytial Virus Infections.
Median enrollment 132 across the 25 interventional studies, 816 across the 5 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSPC Ouyi Pharmaceutical Co., Ltd., one of the names counted as CSPC Pharmaceutical Group Limited. Under that name alone:
CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.
CSPC Pharmaceutical Group Limited has 2 studies filed under Respiratory Syncytial Virus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies in Respiratory Syncytial Virus Infections with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07402512Phase 3Simcere Pharmaceutical Co., LtdA Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children | 2027-03-31 |
| NCT06363370Phase 3Kexing Biopharm Co., Ltd.Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | 2027-06-30 |
| NCT06645665Shenzhen Shenxin Biotechnology Co., LtdA Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above | 2027-04 |
| NCT07582796Ab&B Bio-tech Co., Ltd.JSClinical Trial of Recombinant RSV Vaccine (CHO Cell) (Adjuvanted) in Chinese Population Aged 18 Years and Older. | 2027-09-14 |
Add all 4 to your calendar (.ics) → With an account.
Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of SYH2066 tablets in adult patients with RSV infection. Approximately 80 adult patients with RSV infection are expected to be enrolled and assigned to three active treatment groups and one placebo group, with approximately 20 eligible participants per group. The study consists of a 3-day screening period, a 5-day treatment period, and an 8- to 10-day follow-up period. Throughout the study, safety assessments, PK blood sampling, nasopharyngeal (NP) swab collection, and RSV symptom recording will be performed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet all of the following criteria to be eligible for enrollment in this study:
3. Presence of at least one of the following newly occurring respiratory tract infection symptoms or systemic symptoms (total symptom score ≥3 points); or worsening of pre-existing respiratory symptoms (total symptom score ≥3 points and an increase of at least 2 points from baseline):
Exclusion Criteria:
Participants meeting any of the following criteria will be excluded from this study:
Additional exclusion criteria for COPD participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants will receive the protocol-specified dose orally for 5 days.
Drug: SYH2066
Eligible participants will receive the protocol-specified dose orally for 5 days.
Drug: SYH2066
Eligible participants will receive the protocol-specified dose orally for 5 days.
Drug: SYH2066
Eligible participants will receive the protocol-specified dose orally for 5 days.
Drug: Placebo
Protocol-specified dose of SYH2066 tablets administered orally for 5 days.
Protocol-specified dose of placebo tablets administered orally for 5 days.
Area under the curve (AUC) of RSV RNA viral load measured by RT-qPCR in nasopharyngeal swab samples
Nasopharyngeal swabs will be taken from Day 1 to Day 14 for RSV RNA quantification, and the area under the RSV RNA load-time curve will be derived from the measured values plotted against time.
Time frame: Up to Day 14
Change from baseline in RSV RNA viral load at each visit (D2, D3, D4, D5, D6, D9, D14, ETV)during the study period
Time frame: Up to Day 14
Time from first dose to RSV RNA viral load falling below the lower limit of quantification (LLOQ)
Time frame: Up to Day 14
Percentage of participants with RSV RNA viral load below LLOQ from first dose
Time frame: Up to Day 14
Area under the curve (AUC) of the Respiratory Infection Severity and Impact Questionnaire score from Day 1 to Day 14
Participants need complete the RIIQ questionnaire daily from Day 1 through Day 14, and the area under the time-based score curve will be estimated.
Time frame: Up to Day 14
Change from baseline in the Respiratony Infection Severity and lmpact Questionnaire score at each visit (02, D3,D4,D5, D6, D9, D14, ETV) after first dose
Respiratory Infection Severity and Impact Questionnaire(RiiQ questionnaire) is mainly used to assess RSV symptoms in patients, including upper respiratory tract infection symptoms (sore throat and nasal congestion), symptoms of lower respiratory tract infection (cough, wheezing, sputum, shortness of breath), and system symptoms (fever, headache, neck pain, fatigue, lack of appetite, interrupted sleep, body aches). The questionnaire is divided into four grading categories of severity including none (0), mild (1), moderate (2) and severe (3).
Time frame: Up to Day 14
Time from first dose to resolution/recovery of all RSV symptoms
Resolution/recovery of all RSV symptoms is defined as the concurrent fulfillment of all predefined symptom criteria as specified below, with the response sustained for ≥48 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. RSV symptoms include following: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite).
Time frame: Up to Day 14
Time from first dose to relief of all RSV symptoms
Relief of all RSV symptoms is defined as the concurrent fulfillment of all predefined symptom criteria as specified below, with the response sustained for ≥48 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. RSV symptoms include following: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite).
Time frame: Up to Day 14
Time-weighted average burden of RSV core symptoms (nasal congestion, body aches, sore throat, and cough with phlegm) over 0-96 h post-first dose
It is defined as the AUC of the core symptom burden curve over 0-96 h divided by 96 h, where lower values indicate less overall symptom burden or faster improvement.
Time frame: Up to Day 14
Incidence and severity of adverse events (AEs)
Any abnormalities in vital signs, physical examinations, laboratory tests, 12-lead electrocardiograms (ECGs), or other parameters observed in participants post-dose will be recorded as AEs.
Time frame: Up to Day 14
Time from first dose to resolution/recovery of RSV core symptoms (nasal congestion, body aches, sore throat, cough with phlegm)
Resolution/recovery of RSV core symptoms is defined as the concurrent fulfillment of RSV core symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better.
Time frame: Up to Day 14
Time from first dose to resolution/recovery of respiratory symptoms
Resolution/recovery of respiratory symptoms is defined as the concurrent fulfillment of respiratory symptoms criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Respiratory symptoms include following:stuffy nose, sore throat, cough, expectoration, wheezing, shortness of breath.
Time frame: Up to Day 14
Time from first dose to resolution/recovery of lower respiratory tract symptoms
Resolution/recovery of lower respiratory tract is defined as the concurrent fulfillment of lower respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Lower respiratory tract symptoms include following: cough, expectoration, wheezing, shortness of breath.
Time frame: Up to Day 14
Time from first dose to resolution/recovery of upper respiratory tract symptoms
Resolution/recovery of upper respiratory tract is defined as the concurrent fulfillment of upper respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Upper respiratory tract symptoms include following: stuffy nose, sore throat.
Time frame: Up to Day 14
Time from first dose to resolution/recovery of systemic symptoms
Resolution/recovery of systemic symptoms is defined as the concurrent fulfillment of systemic symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Systemic symptoms include following: feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite.
Time frame: Up to Day 14
Time from first dose to relief of RSV core symptoms (nasal congestion, body aches, sore throat, cough with phlegm)
Relief of RSV core symptoms is defined as the concurrent fulfillment of RSV core symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better.
Time frame: Up to Day 14
Time from first dose to relief of respiratory symptoms
Relief of respiratory symptoms is defined as the concurrent fulfillment of respiratory symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Respiratory symptoms include following: stuffy nose, sore throat, cough, expectoration, wheezing, shortness of breath.
Time frame: Up to Day 14
Time from first dose to relief of lower respiratory tract symptoms
Relief of lower respiratory tract symptoms is defined as the concurrent fulfillment of lower respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Lower respiratory tract symptoms include following: cough, expectoration, wheezing, shortness of breath.
Time frame: Up to Day 14
Time from first dose to relief of upper respiratory tract symptoms
Relief of upper respiratory tract symptoms is defined as the concurrent fulfillment of upper respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Upper respiratory tract symptoms include following: stuffy nose, sore throat.
Time frame: Up to Day 14
Time from first dose to relief of systemic symptoms
Relief of systemic symptoms is defined as the concurrent fulfillment of systemic symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Systemic symptoms include following: feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite.
Time frame: Up to Day 14
Change from baseline in MxA expression levels at each visit (D2, D3, D4, D5, D6, ETV) during the study
Time frame: Up to Day 14
Peak plasma concentration (Cmax)
Time frame: Up to Day 14
Time to maximum plasma concentration (Tmax)
Time frame: Up to Day 14
Terminal elimination half-life (t½)
Time frame: Up to Day 14
Apparent clearance (CL/F)
Time frame: Up to Day 14
Area under the plasma concentration-time curve
Time frame: Up to Day 14
Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.
Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 13 months is above that.
Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Syncytial Virus Infections →
CSPC Ouyi Pharmaceutical Co., Ltd. →